Nevertheless, given its dual role in promoting cancer proliferation and contributing to lymphedema, FABP4 inhibition represents a compelling therapeutic strategy with the potential to address both cancer-related lymphedema and the metabolic alterations associated with cancer progression. This evidence concerns the gene FABP4 and cancer.